Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Afatinib Dimaleate

These are related to the Afatinib Dimaleate news, in which you can learn about the updated information in Afatinib Dimaleate, to help you better understand and expand Afatinib Dimaleate market. Because the market for Afatinib Dimaleate is evolving and changing, so we recommend that you collect our website, and we will show you the latest news on a regular basis.
  • Drug Patent & Exclusivity Expiration Report - Week of Jan 06 2024

    Drug Patent & Exclusivity Expiration Report - Week of Jan 06 2024

    2025-01-06

    This week, there are 8 drugs in the patent and exclusivity list. They are: - AZURITY PHARMACEUTICALS INC's EDARBI, containing active ingredient AZILSARTAN KAMEDOXOMIL - ABBVIE INC's TRILIPIX, containing active ingredient CHOLINE FENOFIBRATE - AZURITY PHARMACEUTICALS INC's EDARBYCLOR, containing active ingredient AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - TEVA NEUROSCIENCE INC's UZEDY, containing active ingredient RISPERIDONE - TEVA PHARMACEUTICAL INDUSTRIES LTD's AIRDUO RESPICLICK, containing active ingredient FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - BLUEPRINT MEDICINES CORP's AYVAKIT, containing active ingredient AVAPRITINIB - BOEHRINGER INGELHEIM's GILOTRIF, containing active ingredient AFATINIB DIMALEATE - CEPHALON INC's TRISENOX, containing active ingredient ARSENIC TRIOXIDE Read More